Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Neural Network-Enabled, Enzymatic cfDNA Methylation Assay for Colorectal Cancer Early Detection.

Cancer prevention research (Philadelphia, Pa.)·2026

Same author

Establishment and Performance Evaluation of a Multiplexed TET2-APOBEC-Mediated cfDNA Methylation Detection Workflow Using qPCR and dPCR Readouts.

Journal of personalized medicine·2026

Same author

Importin α1 contributes to Venezuelan equine encephalitis virus-induced cell death, but is not required for the capsid-mediated blockage of nucleocytoplasmic trafficking.

Frontiers in microbiology·2026

Same author

Overcoming limitations of targeted protein degraders: developments toward reversible, self-assembling degraders.

Future medicinal chemistry·2026

Same author

From consortia discovery to biotech creation: An innovative approach to next-gen Alzheimer's drugs.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same author

Challenges and Potential of Antibody-Drug Conjugates as Prospective Tuberculosis Therapeutics.

Microorganisms·2025

Search research articles

Related Experiment Video

Updated: Dec 28, 2025

Synthesis and Characterization of 1,2-Dithiolane Modified Self-Assembling Peptides

Synthesis and Characterization of 1,2-Dithiolane Modified Self-Assembling Peptides

Published on: August 20, 2018

Novel, Self-Assembling Dimeric Inhibitors of Human β Tryptase.

Sarah F Giardina¹, Douglas S Werner², Maneesh Pingle^1,2

¹Department of Microbiology and Immunology, Weill Cornell Medicine, 1300 York Avenue, Box 62, New York, New York 10065, United States.

Journal of Medicinal Chemistry

|February 15, 2020

Summary

Researchers developed novel heterodimeric inhibitors for beta-tryptase, a key protease. These bivalent small molecules show enhanced potency and selectivity, offering a promising new therapeutic strategy.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

PCR Mutagenesis, Cloning, Expression, Fast Protein Purification Protocols and Crystallization of the Wild Type and Mutant Forms of Tryptophan Synthase

PCR Mutagenesis, Cloning, Expression, Fast Protein Purification Protocols and Crystallization of the Wild Type and Mutant Forms of Tryptophan Synthase

Published on: September 26, 2020

Related Experiment Videos

Last Updated: Dec 28, 2025

Synthesis and Characterization of 1,2-Dithiolane Modified Self-Assembling Peptides

Synthesis and Characterization of 1,2-Dithiolane Modified Self-Assembling Peptides

Published on: August 20, 2018

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

PCR Mutagenesis, Cloning, Expression, Fast Protein Purification Protocols and Crystallization of the Wild Type and Mutant Forms of Tryptophan Synthase

PCR Mutagenesis, Cloning, Expression, Fast Protein Purification Protocols and Crystallization of the Wild Type and Mutant Forms of Tryptophan Synthase

Published on: September 26, 2020

Area of Science:

Biochemistry
Medicinal Chemistry
Pharmacology

Background:

Beta-tryptase is a homotetrameric serine protease with four active sites.
Its structure is amenable to designing bivalent inhibitors that target adjacent sites.

Purpose of the Study:

To design and synthesize novel heterodimeric inhibitors for beta-tryptase.
To evaluate the potency, selectivity, and mechanism of these bivalent inhibitors.

Main Methods:

Utilized diol, hydroxymethyl phenols, benzoyl methyl hydroxamates, and boronic acid chemistries.
Employed target-driven combinatorial chemistry to screen numerous ligand combinations.
Validated inhibition mechanism using X-ray crystallography.
Assessed compound efficacy in HMC1 xenograft models.

Main Results:

Successfully produced self-assembling heterodimeric beta-tryptase inhibitors.
Achieved superior activity and >100-fold potency improvement compared to monomeric inhibitors.
Demonstrated high selectivity against related proteases and good target engagement.
Identified combinations yielding nanomolar inhibition.

Conclusions:

Heterodimeric inhibitors represent a potent strategy for beta-tryptase targeting.
Combinatorial chemistry is effective for developing bivalent small-molecule drugs.
These inhibitors show therapeutic potential for tryptase-related conditions.